Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02908672 · ClinicalTrials.gov registry record · Phase 3
A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 514
- Enrollment target
NCT02908672 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 514 participants.
The verdict
NCT02908672, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 514 participants
- Enrollment target
Study Summary
This is a Phase III, double-blinded, placebo-controlled, randomized, multicenter study designed to evaluate the efficacy, safety, and pharmacokinetics of atezolizumab + cobimetinib + vemurafenib compared with placebo + cobimetinib + vemurafenib in patients with previously untreated BRAFv600 mutation-positive metastatic or unresectable locally advanced melanoma.
Interventions
- DRUG Atezolizumab
- DRUG Vemurafenib
- DRUG Cobimetinib
- DRUG Atezolizumab Placebo
- DRUG Vemurafenib Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 514 participants |
| Start Date | 2017-01-13 |
| Est. Completion | 2024-07-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02908672
The ClinicalTrials.gov registry entry for NCT02908672 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 514 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Atezolizumab is the first listed.
NCT02908672 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02908672 about?
NCT02908672 is a clinical study titled "A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma". This is a Phase III, double-blinded, placebo-controlled, randomized, multicenter study designed to evaluate the efficacy, safety, and pharmacokinetics of atezolizumab + cobimetinib + vemurafenib compared with placebo + cobimetinib + vemurafenib in patients with previously untreated BRAFv600 mutation...
What is the current status of trial NCT02908672?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 514 participants. The study started on 2017-01-13. Estimated completion is 2024-07-01.
What interventions are being tested in trial NCT02908672?
The interventions under investigation include: Atezolizumab (DRUG), Vemurafenib (DRUG), Cobimetinib (DRUG), Atezolizumab Placebo (DRUG), Vemurafenib Placebo (DRUG).
Who is sponsoring clinical trial NCT02908672?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.